US 2004/0006218 A1 · Chlamydia pneumoniae polynucleotides and uses thereof

Abstract

The subject of the invention is the genomic sequence and the nucleotide sequences encoding polypeptides of Chlamydia pneumoniae, such as cellular envelope polypeptides, which are secreted or specific, or which are involved in metabolism, in the replication process or in virulence, polypeptides encoded by such sequences, as well as vectors including the said sequences and cells or animals transformed with these vectors. The invention also relates to transcriptional gene products of the Chlamydia pneumoniae genome, such as, for example, antisense and ribozyme molecules, which can be used to control growth of the microorganism. The invention also relates to methods of detecting these nucleic acids or polypeptides and kits for diagnosing Chlamydia pneumoniae infection. The invention also relates to a method of selecting compounds capable of modulating bacterial infection and a method for the biosynthesis or biodegradation of molecules of interest using the said nucleotide sequences or the said polypeptides. The invention finally comprises, pharmaceutical, in particular vaccine, compositions for the prevention and/or treatment of bacterial, in particular Chlamydia pneumoniae, infections.

An isolated polynucleotide having a nucleotide sequence of a Chlamydia pneumoniae genome, comprising

(a) the a nucleotide sequence of SEQ ID No. 1;
(b) the nucleotide sequence contained within the Chlamydia pneumoniae genomic DNA in ATCC Deposit No. VR 2634;
(c) the nucleotide sequence contained in a clone insert in ATCC Deposit No. 20700, 207001, or 207002;
(d) a nucleotide sequence exhibiting at least 99.9% identity with the sequence of SEQ ID No. 1;
(e) a nucleotide sequence exhibiting at least 80% homology to SEQ ID No:1;
(f) a polynucleotide which hybridizes to SEQ ID No. 1 or to the Chlamydia pneumoniae genomic DNA contained in ATCC deposit No. Vr 2634 or to a clone insert in ATCC Deposit No. 20700, 207001, or 207002 under conditions of high stringency;
(g) a polynucleotide which hybridizes to SEQ ID No. 1 or to the Chlamydia pneumoniae genomic DNA contained in ATCC deposit No. VR 2634 under conditions of intermediate stringency;
(h) a polynucleotide having a nucleotide sequence of an open reading frame (ORF) of a Chlamydia pneumoniae genome, comprising:
(a) a nucleotide sequence chosen from one of ORF2 to ORF 1297;
(b) a nucleotide sequence exhibiting at least 99.9% identity with one of ORF2 to ORF 1297;
or
(c) a nucleotide sequence exhibiting at least 80% homology to one of ORF2 to ORF 1297;
(i) a polynucleotide which hybridizes to one of ORF2 to ORF 1297 under conditions of high stringency;
(j) a polynucleotide which hybridizes to one of ORF2 to ORF 1297 under conditions of intermediate stringency;
(k) a nucleotide sequence which encodes the following polypeptides or fragments thereof:
(a) a Chlamydia pneumoniae transmembrane polypeptide having between 1 and 3 transmembrane domains;
(b) a Chlamydia pneumoniae transmembrane polypeptide having between 4 and 6 transmembrane domains;
(c) a Chlamydia pneumoniae transmembrane polypeptide having at least 7 transmembrane domains;
(d) a Chlamydia pneumoniae polypeptide involved in intermediate metabolism of sugars and/or cofactors;
(e) a Chlamydia pneumoniae polypeptide involved in intermediate metabolism of nucleotides or nucleic acids;
(f) a Chlamydia pneumoniae polypeptide involved in metabolism of amino acids or polypeptides;
(g) a Chlamydia pneumoniae polypeptide having involved in metabolism of fatty acids;
(h) a Chlamydia pneumoniae polypeptide involved in the synthesis of the cell wall;
(i) a Chlamydia pneumoniae polypeptide involved in transcription, translation, and/or maturation process;
(j) a Chlamydia pneumoniae transport polypeptide;
(k) a Chlamydia pneumoniae polypeptide involved in the virulence process;
(l) a Chlamydia pneumoniae polypeptide involved in the secretory system and/or which is secreted;
(m) a Chlamydia pneumoniae polypeptide of the cellular envelope or outer cellular envelope of Chlamydia pneumoniae.
(n) a Chlamydia pneumoniae surface exposed polypeptide;
(o) a Chlamydia pneumoniae lipoprotein;
(p) a Chlamydia pneumoniae polypeptide involved in lipopolysaccharide biosynthesis;
(q) a Chlamydia pneumoniae KDO-related polypeptide;
(r) a Chlamydia pneumoniae phosphomannomutase-related polypeptide;
(s) a Chlamydia pneumoniae lipid A component-related polypeptide;
(t) a Chlamydia pneumoniae phosphoglucomutase-related polypeptide;
(u) a Chlamydia pneumoniae polypeptide that contains an RGD sequence;
(v) a Chlamydia pneumoniae Type III secreted polypeptide;
(w) a Chlamydia pneumoniae cell wall anchored surface polypeptide;
or
(x) a Chlamydia pneumoniae polypeptide that is not found in Chlamydia trachomatis;
or
(l) one of ORF2 to ORF1297 ligated in frame to a polynucleotide encoding a heterologous polypeptide.

39 more elements

Chlamydia pneumoniae polynucleotides and uses thereof

Life of this patent

Chlamydia pneumoniae polynucleotides and uses thereof

Life of this patent

Abstract

Claims26